[Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon].
Adriamycin is one of the chemotherapeutic agent often administered in the treatment of unresectable hepatocellular carcinoma. On monotherapy, the reported rate response is between 0 to 15 p. cent, without improvement on survival. Its combination with other cytotoxic molecules, such as interferon, has been suggested to improve the percentage of response rates. We present the case of a 73 years old man, who underwent a prolonged partial response of a hepatocellular carcinoma with adriamycin and recombinant human interferon alpha-2.
Amiot
X
X
Service d'Hépatogastroentérologie, Hôpital Tenon, Paris.
Grangé
J D
JD
Boudghene
F
F
Lamarque
D
D
Lotz
J P
JP
Izrael
V
V
Bodin
F
F
D000368:Aged; D000437:Alcoholism / Q000150:complications*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods*; D014057:Tomography, X-Ray Computed
D007370:Interferon Type I; D011994:Recombinant Proteins; D004317:Doxorubicin
Rémission partielle prolongée d'un carcinome hépatocellulaire traité par adriamycine et interféron alpha-2 human recombinant.